P. Rema, A. Nath, D. Dinesh, S. Ranjith J, S. Sambasivan
{"title":"591 Perioperative care in gynaecological cancer surgery during the COVID pandemic in a low resource centre – role of enhanced recovery protocols","authors":"P. Rema, A. Nath, D. Dinesh, S. Ranjith J, S. Sambasivan","doi":"10.1136/ijgc-2021-esgo.308","DOIUrl":null,"url":null,"abstract":"Introduction/Background ∗ ERAS (Enhanced Recovery after Surgery) is a multimodal perioperative care pathway designed to achieve early recovery after surgical procedures. This study aimed to analyse the feasibility of ERAS in the era of pandemic and to find its effect on the post-operative outcome of patients undergoing surgery for gynaecological cancer during the COVID pandemic Methodology This observational study was done on patients who underwent gynaecological cancer surgery during COVID pandemic in a tertiary cancer centre in South India. Data was collected including patient demographics, nature of surgery, adherence to each of the components of ERAS programme and outcomes. Post operative complications were graded according to the Clavien-Dindo classification Result(s)∗ 152 patients were included in the study period from June to December 2020. 85 patients had cancer ovary, 59 cancer endometrium, 6 cancer cervix and 1 cancer vulva and 7 patients had benign tumours. In the pre operative component of ERAS protocols,82% patients received pre surgery counselling, 97% received thromboembolic prophylaxis, 94% received carbohydrate loading and none of the patients received mechanical bowel preparation. 8% received blood components during and after surgery. In the post operative phase on Day 1, 62% patients had urinary catheter removed, 88% received normal diet and 92% had early ambulation. The complication rate was 26%, but majority 79% had grade 1 and 2 complications. There was one postoperative mortality due to sepsis. The mean hospital stay was 6.6 days. Conclusion∗ The study confirms the feasibility and benefits of following ERAS pathway in enhancing patient recovery during COVID pandemic.","PeriodicalId":253349,"journal":{"name":"Organization of gynaecological cancer care","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organization of gynaecological cancer care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-esgo.308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction/Background ∗ ERAS (Enhanced Recovery after Surgery) is a multimodal perioperative care pathway designed to achieve early recovery after surgical procedures. This study aimed to analyse the feasibility of ERAS in the era of pandemic and to find its effect on the post-operative outcome of patients undergoing surgery for gynaecological cancer during the COVID pandemic Methodology This observational study was done on patients who underwent gynaecological cancer surgery during COVID pandemic in a tertiary cancer centre in South India. Data was collected including patient demographics, nature of surgery, adherence to each of the components of ERAS programme and outcomes. Post operative complications were graded according to the Clavien-Dindo classification Result(s)∗ 152 patients were included in the study period from June to December 2020. 85 patients had cancer ovary, 59 cancer endometrium, 6 cancer cervix and 1 cancer vulva and 7 patients had benign tumours. In the pre operative component of ERAS protocols,82% patients received pre surgery counselling, 97% received thromboembolic prophylaxis, 94% received carbohydrate loading and none of the patients received mechanical bowel preparation. 8% received blood components during and after surgery. In the post operative phase on Day 1, 62% patients had urinary catheter removed, 88% received normal diet and 92% had early ambulation. The complication rate was 26%, but majority 79% had grade 1 and 2 complications. There was one postoperative mortality due to sepsis. The mean hospital stay was 6.6 days. Conclusion∗ The study confirms the feasibility and benefits of following ERAS pathway in enhancing patient recovery during COVID pandemic.
ERAS (Enhanced Recovery after Surgery)是一种多模式的围手术期护理途径,旨在实现手术后的早期恢复。本研究旨在分析大流行时期ERAS的可行性,并发现其对COVID大流行期间接受妇科癌症手术的患者术后预后的影响。方法本观察性研究是在印度南部的一家三级癌症中心对COVID大流行期间接受妇科癌症手术的患者进行的。收集的数据包括患者人口统计数据、手术性质、对ERAS方案各组成部分的依从性和结果。根据Clavien-Dindo分级对术后并发症进行分级。结果(s)∗在2020年6月至12月的研究期间纳入152例患者。卵巢癌85例,子宫内膜癌59例,宫颈癌6例,外阴癌1例,良性肿瘤7例。在ERAS方案的术前部分,82%的患者接受了术前咨询,97%的患者接受了血栓栓塞预防,94%的患者接受了碳水化合物负荷,没有患者接受机械肠道准备。8%的患者在手术中和手术后接受了血液成分检测。术后第1天,62%的患者拔除了导尿管,88%的患者恢复正常饮食,92%的患者可以早期下床。并发症发生率为26%,但大多数(79%)有1级和2级并发症。术后因败血症死亡1例。平均住院时间为6.6天。结论*本研究证实了ERAS途径在COVID大流行期间增强患者康复的可行性和益处。